January 07, 2005

Gene Test to Determine Med Doses

Read more... Schizophrenia Biology

The FDA has just approved the first-ever laboratory test system that will allow physicians to observe certain portions of a patient's genetic information. The results of this test can be used to help select medications and dosages that may be more compatible with that person's unique biology.

The DNA microarray test analyzes the genetic information from the "cytochrome P450" gene family. These genes code for enzymes that act in the liver to metabolize drugs and other foreign compounds in the body. Specifically, this test looks at variations in a gene that codes the enzyme P4502D6, which the rate of metabolism of some common antidepressants, antipsychotics, beta-blockers, and chemotherapy drugs.

Although this microarray analysis is not intended to be the only factor in determining drug choice and dosage, it will be a valuable tool alongside clinical and medical history evaluations.

The AmpliChip Cytochrome P450 Genotyping Test is made by Roche Molecular Systems, and will operate with the Affymetric Genechip Microarray Instrumentation System (Affymetrix).

To read the full FDA news release, see: "FDA Clears First of Kind Genetic Lab Test" (Dec 23, 2004). Available at http://www.fda.gov

Read about another genetic test for medication compatibility on the horizon: "Future Clozapine Compatibility Genetic Test." Schizophrenia Newsblog Entry, Dec 20 2004.


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required